Purpose: Brinzolamide and dorzolamide are often used as adjunctive therapy to other
antiglaucoma agents. The purpose of this study was to compare the efficacy and safety of
brinzolamide 1% versus dorzolamide 1% when added to the combination therapy of latanoprost
and a beta-blocker in patients with glaucoma.
Methods: An 8-week, randomized, open-label comparative study was performed in 52 patients
with glaucoma. Brinzolamide 1% (twice a day) or dorzolamide 1% (3 times a day) was
randomly administered to the patients who had been treated with both latanoprost and a betablocker.
Results: Intraocular pressure (IOP) were both decreased significantly (P < 0.0001) from
18.6 ± 2.3 mmHg to 16.7 ± 2.3 mmHg and from 18.4 ± 2.6 mmHg to 16.6 ± 2.5 mmHg, respectively,
8 weeks after the addition of brinzolamide or dorzolamide. However, the difference
between the groups was not significant (P = 0.86). The incidence of ocular irritation was
significantly higher (P < 0.0001) in the dorzolamide group (74%) than the brinzolamide group
(16%), but there was no significant difference in blurred vision between the groups (dorzolamide
37% versus brinzolamide 52%, P = 0.40).
Conclusions: We concluded that the efficacy of brinzolamide 1% was equivalent to dorzolamide
1%; however, the safety of brinzolamide 1% was superior to dorzolamide 1% as adjunctive
therapy to the combination with latanoprost and a beta-blocker.
